论文部分内容阅读
目的探讨不同剂量瑞舒伐他汀对冠心病患者血脂、肱动脉内皮依赖性舒张功能(FMD)及颈动脉内膜中层厚度(IMT)的影响。方法 100例冠心病患者作为研究对象,均给予瑞舒伐他汀治疗,根据使用剂量的不同分为对照组和观察组,每组50例。观察组患者给予瑞舒伐他汀20 mg/d治疗,对照组患者给予瑞舒伐他汀10 mg/d治疗,治疗8周,对比两组血脂、肱动脉FMD及IMT水平。结果治疗后,观察组患者的血清总胆固醇(TC)为(4.12±0.65)mmol/L,低密度脂蛋白胆固醇(LDL-C)为(2.13±0.80)mmol/L;对照组患者的TC为(4.99±0.88)mmol/L,LDL-C为(2.49±0.73)mmol/L;治疗后两组的TC和LDL-C水平均较治疗前显著降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。两组治疗前后甘油三酯(TG)和高密度脂蛋白胆固醇(HDL-C)水平比较差异均无统计学意义(P>0.05)。治疗前,观察组患者的FMD、IMT分别为(9.21±1.11)%、(1.10±0.21)mm,对照组分别为(9.18±1.10)%、(1.08±0.20)mm;治疗后,观察组患者的FMD、IMT分别为(13.52±1.12)%、(0.70±0.22)mm,对照组分别为(12.2±1.20)%、(0.86±0.21)mm。两组的FMD值均较治疗前显著提高,且观察组明显高于对照组,差异均具有统计学意义(P<0.05)。治疗后两组的IMT值均较治疗前显著下降,且观察组下降幅度大于对照组,差异均具有统计学意义(P<0.05)。结论瑞舒伐他汀治疗冠心病疗效确切,给予20 mg/d剂量治疗较10 mg/d剂量而言,改善患者FMD和IMT的效果更好。
Objective To investigate the effects of different dosages of rosuvastatin on blood lipid, brachial artery endothelium-dependent diastolic function (FMD) and carotid intima-media thickness (IMT) in patients with coronary heart disease. Methods 100 patients with coronary heart disease were treated with rosuvastatin. The patients were divided into control group and observation group with 50 cases in each group. Patients in the observation group were treated with rosuvastatin 20 mg / d. Patients in the control group were given rosuvastatin 10 mg / d for 8 weeks. The levels of lipid and brachial artery FMD and IMT were compared between the two groups. Results After treatment, the total cholesterol (TC) in the observation group was (4.12 ± 0.65) mmol / L and the LDL-C was (2.13 ± 0.80) mmol / L. The TC in the control group was (4.99 ± 0.88) mmol / L and LDL-C (2.49 ± 0.73) mmol / L, respectively. After treatment, the levels of TC and LDL-C in both groups were significantly lower than those before treatment, and the levels in the observation group were lower than those in the control group Statistical significance (P <0.05). There was no significant difference in triglyceride (TG) and high density lipoprotein cholesterol (HDL-C) between the two groups before and after treatment (P> 0.05). Before treatment, FMD and IMT in the observation group were (9.21 ± 1.11)% and (1.10 ± 0.21) mm, respectively, and those in the control group were (9.18 ± 1.10) and (1.08 ± 0.20) mm respectively The FMD and IMT were (13.52 ± 1.12)% and (0.70 ± 0.22) mm respectively in the control group and (12.2 ± 1.20)% and (0.86 ± 0.21) mm respectively in the control group. The FMD of both groups were significantly higher than those before treatment, and the observation group was significantly higher than the control group, the differences were statistically significant (P <0.05). After treatment, the IMT values of both groups were significantly lower than those before treatment, and the decrease rate of the observation group was greater than that of the control group, with significant difference (P <0.05). Conclusions Rosuvastatin is effective in treating coronary heart disease. The treatment with 20 mg / d dose is better than the 10 mg / d dose in improving FMD and IMT.